GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » Price-to-Owner-Earnings

Omeros (Omeros) Price-to-Owner-Earnings : 2.08 (As of Apr. 30, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Omeros Price-to-Owner-Earnings?

As of today (2024-04-30), Omeros's share price is $3.16. Omeros's Owner Earnings per Share (TTM) ended in Dec. 2023 was $1.52. It's Price-to-Owner-Earnings for today is 2.08.


The historical rank and industry rank for Omeros's Price-to-Owner-Earnings or its related term are showing as below:

OMER' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0   Med: 0   Max: 6.66
Current: 2.12

During the past 13 years, the highest Price-to-Owner-Earnings of Omeros was 6.66. The lowest was 0.00. And the median was 0.00.


OMER's Price-to-Owner-Earnings is ranked better than
97.63% of 169 companies
in the Biotechnology industry
Industry Median: 32.37 vs OMER: 2.12

As of today (2024-04-30), Omeros's share price is $3.16. Omeros's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.88. Therefore, Omeros's PE Ratio for today is At Loss.

As of today (2024-04-30), Omeros's share price is $3.16. Omeros's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.78. Therefore, Omeros's PE Ratio without NRI for today is At Loss.


Omeros Price-to-Owner-Earnings Historical Data

The historical data trend for Omeros's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Price-to-Owner-Earnings Chart

Omeros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.52 - 2.15

Omeros Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.17 4.44 3.85 2.15

Competitive Comparison of Omeros's Price-to-Owner-Earnings

For the Biotechnology subindustry, Omeros's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omeros's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Omeros's Price-to-Owner-Earnings falls into.



Omeros Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Omeros's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.16/1.52
=2.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omeros  (NAS:OMER) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Omeros Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Omeros's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Omeros (Omeros) Business Description

Traded in Other Exchanges
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Executives
Demopulos Gregory A Md director, 10 percent owner, officer: Chairman, CEO & President 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Demopulos Peter A Md director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Arnold C Hanish director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas J. Cable director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Diana T. Perkinson director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Michael A Jacobsen officer: VP Finance and CAO 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Kurt Zumwalt director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Peter B Cancelmo officer: See Remarks 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas F. Bumol director 201 ELLIOT AVENUE WEST, SEATTLE WA 98119
Marcia S. Kelbon officer: VP Patent and General Counsel 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Ray Aspiri director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Hood Leroy E. Md Phd director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Rajiv Shah director C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Jean-philippe Tripet director 1420 FIFTH AVENUE, SUITE 2600, SEATTLE WA 98101-2347